NRG
ONC

Nemes Rush Group’s BeOne Medicines Ltd ONC Stock Holding History

Nemes Rush Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Hold
4
– – ﹤0.01% 850
2026
Q1 		$1.19K Hold
4
– – ﹤0.01% 805
2025
Q4 		$1.22K Buy
+4
New +$1.31K ﹤0.01% 791

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nemes Rush Group's ONC Position: Q2 2026 in Review

Nemes Rush Group held its BeOne Medicines Ltd (ONC) position steady in Q2 2026 at 4 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Nemes Rush Group first reported a position in ONC in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.22K in Q4 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Nemes Rush Group held 4 shares of BeOne Medicines Ltd worth $1.14K as of Q2 2026.
  • Nemes Rush Group left its BeOne Medicines Ltd share count unchanged in Q2 2026.
  • BeOne Medicines Ltd made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #850 holding.
  • Nemes Rush Group first reported a position in BeOne Medicines Ltd in Q4 2025 and has held it in 3 quarters since.
  • Nemes Rush Group's BeOne Medicines Ltd position peaked at $1.22K in Q4 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.